Biohaven

Biohaven Net Tangible Assets

The Net Tangible Assets of Biohaven (BHVN) as of Oct 28, 2026 is 50.68 M USD. In the previous year, Net Tangible Assets was 403.65 M USD — a change of -87.44% (lower).

Net Tangible Assets

50.68 MUSD

YoY

-87.44%

Last updated:

Net Tangible Assets of Biohaven is 2025 50.68 M USD. Net Tangible Assets of Biohaven was 2024 403.65 M USD. It decreases by -87.44% lower compared to the previous year.

The Biohaven Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
150.92 M USD
Jan 1, 2019
-7.42 M USD
Jan 1, 2020
76.78 M USD
Jan 1, 2021
74.90 M USD
Jan 1, 2022
518.98 M USD
Jan 1, 2023
408.19 M USD
Jan 1, 2024
403.65 M USD
Jan 1, 2025
50.68 M USD
The Biohaven Net Tangible Assets history
YEARNet Tangible AssetsYoY
50.68 MUSD-87.44%
403.65 MUSD-1.11%
408.19 MUSD-21.35%
518.98 MUSD+592.89%
74.90 MUSD-2.45%
76.78 MUSD-1,134.23%
-7.42 MUSD-104.92%
150.92 MUSD+14.36%
131.97 MUSD-7,431.72%
-1.80 MUSD-263.64%
1.10 MUSD-31.25%
1.60 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Net Tangible Assets of Biohaven is 50.68 M USD in 2025.

Net Tangible Assets of Biohaven changed from 403.65 M USD to 50.68 M USD, representing a -87.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Biohaven since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biohaven

All Key Metrics — Biohaven